In a recent study, 15 adults aged 19 to 25 with ADHD were randomized to receive mixed amphetamine salts XR or placebo for 3 weeks and were then crossed over to the other group for another 3 weeks.

Analysis of the National Comorbidity Replication Survey revealed that 3% of a nationally representative sample of 10,000 US adults satisfied diagnostic criteria for ADHD, and that more than one third of those diagnosed with ADHD had not been diagnosed until adulthood. Once thought to be primarily a disorder of childhood, ADHD is now known to frequently extend into adolescence and adulthood. TORONTO, Canada-Treatment with mixed amphetamine salts extended release (XR) (Adderall XR) improves information processing speed and accuracy in adults with attention-deficit/hyperactivity disorder (ADHD), according to findings presented at the annual meeting of the American Psychiatric Association. Treatments need to include the targeting of the ADHD symptoms effectively in order to achieve better resolution of anxiety symptoms.From the American Psychiatric Association Not Just a Childhood Disease Larger controlled studies are needed to support the effectiveness of mixed amphetamine salts in patients with comorbid anxiety symptoms. Mixed amphetamine salts MAS-XR can be used in adult patients with ADHD and comorbid anxiety symptoms. There was decrease in mean weight at 12 weeks by 2.2 kg (P <.

Patients tolerated the treatment, and there were no significant cardiovascular changes at 12 weeks. Also there was significant reduction in the disability score at 12 weeks. There was significant and robust resolution of symptoms of all effectiveness measures, including the symptoms of anxiety, as shown by changes from baseline in HAM-A, ASRS-v1.1, and CGI at 8 weeks. All patients completed this open-label trial. Monitoring for pulse, blood pressure, and weight changes was carried out at baseline and at end point. Baseline measures prior to the treatment with MAS-XR were compared to those at 4, 8, and at 12 weeks of treatment. Other scales included the Hamilton Anxiety Scale (HAM-A), the adult ADHD Self-Report Scale (ASRS-v1.1) symptom checklist, and Sheehan's disability scale. The primary effectiveness measure was the Clinical Global Impression severity subscale (CGI-S). All patients were treated with the 'Mixed Amphetamine salts Extended Release Adderall XR, (MAS-XR), as adjunctive to SSRIs or to SNRIs and were followed for at least 12 weeks. All patients had significant comorbid anxiety symptoms (HAM-A > 7) and failed to respond to 8-week trials of Serotonin Reuptake Inhibitors (SSRIs) or Norepinephrine Reuptake inhibitors (SNRIs). Consenting adult patients (n = 32) with confirmed diagnosis of generalized anxiety (GA) and comorbid (ADHD) participated in this open-label study. To examine the changes in partially responsive anxiety symptoms utilizing adjunctive treatment with the mixed amphetamine salt extended release (Adderall XR, MAX-XR) in the treatment of adult ADHD patients, with comorbid refractory anxiety.